Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting

Kirsty McCance (Lead / Corresponding author), Helen Wise, Jennifer Simpson, Becky Batchelor, Harriet Hale, Lindsay McDonald, Azul Zorzoli, Elizabeth Furrie, Charu Chopra, Frauke Muecksch, Theodora Hatziioannou, Paul D. Bieniasz, Kate Templeton, Sara Jenks

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
35 Downloads (Pure)


SARS-CoV-2 antibody tests have been marketed to diagnose previous SARS-CoV-2 infection and as a test of immune status. There is a lack of evidence on the performance and clinical utility of these tests. We aimed to carry out an evaluation of 14 point of care (POC) SARS-CoV-2 antibody tests. Serum from participants with previous RT-PCR (real-time polymerase chain reaction) confirmed SARS-CoV-2 infection and pre-pandemic serum controls were used to determine specificity and sensitivity of each POC device. Changes in sensitivity with increasing time from infection were determined on a cohort of study participants. Corresponding neutralising antibody status was measured to establish whether the detection of antibodies by the POC device correlated with immune status. Paired capillary and serum samples were collected to ascertain whether POC devices performed comparably on capillary samples. Sensitivity and specificity varied between the POC devices and in general did not meet the manufacturers' reported performance characteristics, which signifies the importance of independent evaluation of these tests. The sensitivity peaked at ≥20 days following onset of symptoms, however sensitivity of 3 of the POC devices evaluated at extended time points showed that sensitivity declined with time. This was particularly marked at >140 days post infection. This is relevant if the tests are to be used for sero-prevalence studies. Neutralising antibody data showed that positive antibody results on POC devices did not necessarily confer high neutralising antibody titres, and that these POC devices cannot be used to determine immune status to the SARS-CoV-2 virus. Comparison of paired serum and capillary results showed that there was a decline in sensitivity using capillary blood. This has implications in the utility of the tests as they are designed to be used on capillary blood by the general population.

Original languageEnglish
Article numbere0266086
Number of pages18
JournalPLoS ONE
Issue number3
Publication statusPublished - 31 Mar 2022


Dive into the research topics of 'Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting'. Together they form a unique fingerprint.

Cite this